Pulmonary veno-occlusive disease, a rare cause of pulmonary hypertension, is characterized by extensive and diffuse occlusion of pulmonary veins by fibrous tissue. Although the diagnosis can be suspected by the presence of the classic clinical triad of severe pulmonary arterial hypertension, radiographic evidence of pulmonary hypertension and edema, and normal pulmonary artery occlusion pressure, the definitive diagnosis is histopathologic. The prognosis of pulmonary veno-occlusive disease is poor with most described patients dying within 2 years of diagnosis. Although anti-coagulation, oxygen, and vasodilator therapies are effective temporarily, the definitive treatment is lung transplantation. We describe the recurrence of pulmonary veno-occlusive disease at 3 months after heart-lung transplantation in a 26-year-old man. Recurrence after transplantation for this disease has not been reported previously, and lung transplantation was thought to be definitive treatment. With this 1st report of ...

The bronchial circulation undergoes angiogenesis in several pathological conditions, such as lung neoplasm and bronchiectasis, but whether the pulmonary circulation can do this has been questioned. A woman treated with mitomycin C and 5-fluorouracil developed progressive, fatal pulmonary hypertension over 5 months. In addition to light and transmission electron microscopic examination of her lung, her pulmonary vasculature was cast and the casts were studied with scanning electron microscopy. Light microscopy showed that she had pulmonary veno-occlusive disease and angiomatoid capillary growth in the alveolar walls. Transmission electron microscopy confirmed the presence of pulmonary hypertension and showed thickened endothelial basement membrane. Scanning electron microscopy of the cast blood vessels showed distortion and destruction of alveolar capillaries prohibiting the passage of erythrocytes. Large new capillaries developed on top of, and were connected to, the shrivelled capillaries that ...

Pulmonary veno-occlusive disease (PVOD) is a disorder which causes progressive pulmonary hypertension, usually presenting with worsening dyspnoea and right heart failure. Pulmonary oedema induced by pulmonary vasodilator therapy to reduce pulmonary arterial pressure has been well described in PVOD, but here we describe a case of PVOD presenting with recurrent episodes of acute non-cardiogenic pulmonary oedema, in the absence of significant pulmonary hypertension. Concern over the risk of precipitating pulmonary oedema led us to use inhaled nitric oxide to predict the safety and efficacy of sildenafil.. ...

PVOD is a rare and incompletely understood cause of PAH with a grave prognosis. Lung transplantation is the only curative option, without which mortality is 72% at 1 year.1 Presentation is usually similar to PAH with progressive dyspnoea and pulmonary hypertension, but may be acute, even presenting with sudden death.2 The characteristic radiographic appearances are interlobular septal thickening, ground glass shadowing and mediastinal lymphadenopathy.. The cause of PVOD remains unclear, although associations with multiple conditions have been reported.1 The characteristic progressive and patchy narrowing and occlusion of the small postcapillary pulmonary veins causes heterogeneous areas of increased pulmonary capillary pressure, ultimately leading to pulmonary hypertension and oedema. This is in contrast with another cause of non-cardiogenic pulmonary oedema, high altitude pulmonary oedema, which induces pulmonary oedema and hypertension through exaggerated heterogeneous pulmonary arterial ...

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited ...

PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Pulmonary vascular disease is defined as a condition of blood flow to the lungs artery is blocked suddenly due to a blood clot somewhere in the body, including pulmonary embolism, chronic thromboembolic disease, pulmonary arterial hypertension, pulmonary veno-occlusive disease, pulmonary arteriovenous malformations, pulmonary edema, etc. Pulmonary arterial hypertension Pulmonary arterial hypertension is a subgroup of …. ...

Pulmonary vascular disease is defined as a condition of blood flow to the lungs artery is blocked suddenly due to a blood clot somewhere in the body, including pulmonary embolism, chronic thromboembolic disease, pulmonary arterial hypertension, pulmonary veno-occlusive disease, pulmonary arteriovenous malformations, pulmonary edema, etc. Pulmonary arterial hypertension Pulmonary arterial hypertension is a subgroup of …. ...

Pulmonary veno-occlusive disease is a rare subcategory of pulmonary arterial hypertension (WHO Group 1). The disease is poorly understood and difficult to diagnose; it has no definitive cure to date. These patients present with nonspecific symptoms, including dyspnea, exercise intolerance, and weakness. Chest x-rays sometimes differ from idiopathic pulmonary arterial hypertension and may demonstrate alveolar infiltrates and pleural effusions. High resolution computed tomography scans reveal ground glass opacities, interlobular septal thickening, and lymphadenopathy. Echocardiography can estimate the level of pulmonary artery pressures; right heart catheterization is needed for complete hemodynamic characterization of these patients. Lung biopsies demonstrate remodeling of the venules and small veins with intimal and adventitial fibrosis. This can result in total venous occlusion and subsequent recanalization. Similar changes occur in the small arteries and arterioles but are less pronounced than ...

Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia (risk of vaso-occlusive crisis). Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP,90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy. Nursing mothers.. ...

Congenital Pulmonary Veins Atresia or Stenosis: Read more about Symptoms, Diagnosis, Treatment, Complications, Causes and Prognosis.

In the article by Fender et al, Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes, which published online before print October 28, 2016, and appeared in the December 6, 2016, issue of Circulation (Circulation. 2016;134:1812-1821. DOI: 10.1161/CIRCULATIONAHA.116.021949), a correction is needed. The following statement contained a mathematical error:. Thirteen veins (12%) were taken to the catheterization laboratory but not intervened on as they were found to have ,50% narrowing on venography and only an insignificant pressure gradient was measured despite the pre-procedure CT showing ,75% narrowing.. The sentence should read as follows:. Thirteen veins (6%) were taken to the catheterization laboratory but not intervened on as they were found to have ,50% narrowing on venography and only an insignificant pressure gradient was measured despite the pre-procedure CT showing ,75% narrowing.. The correction has been made to ...

TY - JOUR. T1 - Endoscopic treatment of cerebrospinal fluid pathway obstructions. T2 - Commentary. AU - Komotar, Ricardo J.. AU - Connolly, E. Sander. PY - 2008/6/1. Y1 - 2008/6/1. UR - http://www.scopus.com/inward/record.url?scp=57049101803&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=57049101803&partnerID=8YFLogxK. U2 - 10.1227/01.NEU.0000249242.17805.E3. DO - 10.1227/01.NEU.0000249242.17805.E3. M3 - Comment/debate. AN - SCOPUS:57049101803. VL - 62. SP - SHC1091. JO - Neurosurgery. JF - Neurosurgery. SN - 0148-396X. IS - 6 SUPPL.. ER - ...

The left atrium and pulmonary veins initially develop separately in the 3- to 5-mm embryo (25 to 27 days gestation).1 The primordial pulmonary venous system is part of the splanchnic plexus, which initially connects to the cardinal and umbilicovitelline veins. At 27 to 29 days gestation, a small endothelial outgrowth from the posterior superior wall of the primordial left atrium develops just to the left of the developing septum primum. At 28 to 30 days gestation, this common pulmonary venous out-pouching engages the pulmonary venous portion of the splanchnic plexus and begins to drain blood from the pulmonary system. In normal development, the connections to the cardinal and umbilicovitelline systems atrophy, which results in complete separation between the pulmonary and systemic venous systems.. The sequence of connection of the out-pouching of the left atrium to the pulmonary venous plexus, followed by incorporation of the confluence of the common pulmonary venous system into the left atrium, ...

A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.

Measurements were made of simultaneous pulmonary artery wedge (PAw) and left ventricular diastolic (LVed) pressures 39 times during 21 venous and left ventricular cardiac catheterization studies in eight animals with brisket disease. Each animal was studied during the acute phase of the disease. The remaining 13 studies were carried out in six animals at various intervals during spontaneous recovery from pulmonary hypertension and heart failure. A pressure gradient between PAw and LVed (δP) which averaged 14.6 ± 1.6 (SE) mm Hg was demonstrated in 12 measurements during seven studies in four animals (group A). The δP in 27 measurements during 14 studies in six animals averaged 2.4 ±0.8 mm Hg (group B). Venous resistance (Rv) represented 39±5% of the total resistance (RT) of pulmonary vessels in group A and 13±4% in group B studies. The δP and Rv/RT in group A animals are consistent with findings caused by pulmonary venous obstruction. The obstruction was interpreted to represent the effect ...

Doppler (A) and MR imaging (B: pre ablation, C: post ablation) of PV in patients with pulmonary vein stenosis that developed after PVI. The white arrow showed s

Northside Vascular Surgery offers services to treat vascular and peripheral vascular diseases, such as Carotid Artery Disease, Coronary Artery Disease, Carotid Artery Blockages, Peripheral Venous Disease, Abdominal Aortic Aneurysm and Pulmonary Vein Stenosis

Astfel, substantele din care se prepara remediile isi pierd eventuala toxicitate si potentialul de a produce reactii adverse. Patologia orbitară Stenturi şi catetere utilizate în obstrucţia căilor lacrimale Stents and intubation devices used in lacrimal pathway obstruction Alina Daniela Popa Cherecheanu1, Vlad Budu2 1. Aceasta inrautatire a simptomelor arata ca remediul a fost ales bine si ca isi face efectul.

Inflectra is an immunosuppressive drug and is commonly referred to as a biologic, which is chemically comparative to Remicade, with the active constituent being infliximab. This medication is a laboratory-synthesized antibody, specifically IgG1κ monoclonal antibody, which has the ability to bind strongly to a pro-inflammatory immune protein called tumour necrosis factor alpha (TNFα), and therefore functions to reduce inflammation particularly in cases of autoimmune conditions. Studies have shown that infliximab prevents the development of arthritis in mice. Even after the onset of diseases like arthritis, infliximab helps the healing process of joints. ...

BACKGROUND:Pulmonary capillary hemangiomatosis (PCH) and pulmonary veno-occlusive disease (PVOD) are rare diseases that share clinical, X-ray, and histological features. Most patients have poor prognosis due to severe respiratory impairment. Recently, EIF2AK4 mutations were found in some patients with PCH and PVOD, but the role of this mutation is still unknown. We report an autopsy case of PCH and discuss a mechanism of respiratory dysfunction based on an electron microscopy study. CASE REPORT:The patient was a Japanese man in his sixties. He suffered from acute exacerbation of dyspnea during treatment of COPD. Respiratory function testing revealed DLCO 32.1% and DLCO/VA 23.6%. Echocardiography demonstrated findings consistent with pulmonary hypertension. A CT scan showed mild emphysema and small ground-glass opacity in the lungs. However, we could not find the exact cause of his respiratory failure and he died 28 days after admission. At autopsy, the histology showed multilayering capillary

TY - JOUR. T1 - Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients. T2 - A new classification from the European Society for Blood and Marrow Transplantation. AU - Mohty, M.. AU - Malard, F.. AU - Abecassis, M.. AU - Aerts, E.. AU - Alaskar, A. S.. AU - Aljurf, M.. AU - Arat, M.. AU - Bader, P.. AU - Baron, F.. AU - Bazarbachi, A.. AU - Blaise, D.. AU - Ciceri, F.. AU - Corbacioglu, S.. AU - Dalle, J. H.. AU - Dignan, F.. AU - Fukuda, T.. AU - Huynh, A.. AU - Masszi, T.. AU - Michallet, M.. AU - Nagler, A.. AU - NiChonghaile, M.. AU - Okamoto, S.. AU - Pagliuca, A.. AU - Peters, C.. AU - Petersen, F. B.. AU - Richardson, P. G.. AU - Ruutu, T.. AU - Savani, B. N.. AU - Wallhult, E.. AU - Yakoub-Agha, I.. AU - Duarte, R. F.. AU - Carreras, E.. N1 - Publisher Copyright: © 2016 Macmillan Publishers Limited.. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a ...

We present the case of a patient with colon cancer who, while receiving bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD). Certain antitumour agents such as 6-mercaptopurine and 6-thioguanine have also been reported to initiate hepatic SOSVOD in isolated cases. There have been no reports so far correlating bevacizumab with SOSVOD. A 77-year-old man was being treated with oxaliplatin and a modified de Gramont regimen of 5-fluorouracil for metastatic colon cancer. Bevacizumab (7.5 mg/kg) was added from the seventh cycle onwards. Protracted neutropenia and thrombocytopenia led to discontinuation of oxaliplatin after the ninth cycle. A computed tomography scan showed complete response and bevacizumab was continued for another 3 months, after which time the patient developed right hypochondrial pain, transudative ascites, splenomegaly and abnormal liver function tests. Upper gastrointestinal endoscopy showed oesophageal varices. Liver biopsy showed features considered

Veno-occlusive disease (VOD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prophylactic use of defibrotide (DF) might further reduce VOD rates but has no impact on the incidence of severe VOD or VOD-associated mortality. We investigated the cost-effectiveness of prophylactic DF according to the British Committee for Standards in Haematology/British Society for Blood and Marrow Transplantation guidelines in 348 children who underwent transplantation between 2001 and 2014 in our hospital, 138 of whom were at risk for VOD. The VOD incidence was 7.4% for the total cohort. Patients at risk had a higher incidence of VOD compared with patients without risk factors (15.2% versus 2.4%, P | .0001). VOD occurred more often in patients after busulfan-based myeloablative conditioning than in patients after total body irradiation (11.2% versus 3.5%, P = .001). Donor types or the transplantation-related mortality (TRM) risk score did not correlate with VOD incidence.

Veno-occlusive disease (VOD) occurs when the small blood vessels that lead into and are inside the liver become blocked. VOD is caused by chemotherapy and radiation therapy given during conditioning or intensive therapy before stem cell transplant. It develops in the first few weeks after a stem cel

CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell ...

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541 ...

Along with graft versus host disease (GVHD) and cytomegalovirus (CMV) infection, veno-occlusive disease (VOD) or Sinusoidal Obstruction Syndrome (SOS), is one of the most frequently encountered serious complications after stem cell transplantation. The reported overall incidence rate of veno-occlusive disease ranges from 5% to more than 60% i...

In this study, we present the results of 40 consecutive patients who underwent Senning procedure between September 1983 - March 1992. Mean age at operation was 28 months (range 4 months to 9 years). Early postoperative mortality was 9.5% (2/21, 70% confidence limit; 3,1% - 21%) in the patients with simple TGA. Seven of 19 patients with complex TGA (TGA + VSD + PH/PS) died in the early postoperative period. Persistant pulmonary hypertention was the main reason for early deaths in the patients with TGA + VSD + PH (5/9,55%, 70% CI:38%-75%). In the group of TGA + VSD + PS, 2 patients were died (20%, 70% CI; 7%-40%). Mean follow up is 44 months (2 to 102 months). Only one late death was happened due to endocarditis. All surviving 30 patients are doing well. Their periodical examinations and Doppler echocardiographic controls showed neither systemic nor pulmonary venous obstruction. They are in NYHA functional class I or II. Because of the decreased early mortality rates and the satisfying medium / ...

The first reported percutaneous angioplasty with self-apposing DES implantation for pulmonary vein stenosis: a one year follow- ...

The FDA took the action after Seattle Genetics disclosed six patients taking vadastuximab talirine had signs of liver toxicity including several cases of veno-occlusive disease, where blood flow is blocked in the liver. Four of the patients died.. Veno-occlusive disease most often occurs in patients undergoing blood cell transplantation, one of the treatments for AML, so it isnt clear if vadastuximab talirine is causing the problem. More than 300 patients have been treated with vadastuximab talirine to date, so its a fairly rare problem.. The FDA placed a full hold -- meaning no more treatments until its lifted -- on a phase 1/2 trial testing vadastuximab talirine in pre- and post-allogeneic transplant AML patients. Two other phase 1 trials for vadastuximab talirine are only on a partial hold, so no new patients can be enrolled but existing patients can continue treatment if they want to.. Interestingly, the FDA didnt place other clinical trials testing vadastuximab talirine on clinical ...

Learn about the causes, symptoms, diagnosis & treatment of Vascular Disorders of the Liver from the Professional Version of the Merck Manuals.

Paul G. Richardson, Marcie L. Riches, Nancy A. Kernan, Joel A. Brochstein, Shin Mineishi, Amanda M. Termuhlen, Sally Arai, Stephan A. Grupp, Eva C. Guinan, Paul L. Martin, Gideon Steinbach, Amrita Krishnan, Eneida R. Nemecek, Sergio Giralt, Tulio Rodriguez, Reggie Duerst, John Doyle, Joseph H. Antin, Angela Smith, Leslie ...

Press release - Future Market Insights - Veno-Occlusive Hepatic Disease Therapeutics Market Growth and Forecast 2017-2027 - published on openPR.com

Hepatic ischemia/reperfusion (We/R) injury is usually a major cause of morbidity and mortality after liver surgery. (I/R) injury is a frequently encountered problem 193022-04-7 IC50 in close association with a number of clinical conditions, including liver transplantation, Pringle maneuver during tumor resection, liver trauma, veno-occlusive disease, hemorrhagic shockCresuscitation, and heart failing1,2. Hepatocellular harm in hepatic […]. ...

Stem Cell or Bone Marrow Transplant Side EffectsMouth and throat pain. Mucositis (inflammation or sores in the mouth) is a short-term side effect that can happen with chemo and radiation. … Nausea and vomiting. … Infection. … Bleeding and transfusions. … Interstitial pneumonitis and other lung problems. … Graft-versus-host disease. … Hepatic veno-occlusive disease (VOD) … Graft failure.More items…•Mar 20, ...

You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...

fatigue in MS patients correlated with autonomic dysfunction and postulated that that this was possibly due to lesions impacting on the a sympathetic vasomotor. However, while these investigators performed standard autonomic control tests on MS patients, none measured the changes in the extracranial venous flow rate that occur when subjects move from the supine to upright position. When supine, the IJVs generally act as the principle route by which blood drains from the brain, whereas when upright, their role becomes minimal, with the vast majority of the blood traveling either down the VVs or through other venous pathways [13, 14]. In Doepp et als study both cohorts conformed to this norm when supine, whereas only the healthy controls did when upright - a situation that is highly unusual. Doepp et als results therefore suggest that, rather than any autonomic cause, the rerouting of blood in MS patients occurs as a result of stenosis which primarily affects the venous pathways that are ...

Diagnosis of total anomalous pulmonary venous connection (TAPVC) (costs for program #187659) ✔ Multispecialty Medical Center Preventicum ✔ Department of Cardiology ✔ BookingHealth.com

Diagnosis of total anomalous pulmonary venous connection (TAPVC) (costs for program #194499) ✔ Academic Hospital Eichsfeld ✔ Department of Pediatric and Adolescent Medicine ✔ BookingHealth.com

Learn more about Total Anomalous Pulmonary Venous Connection -- Child at Medical City Dallas DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...

Learn more about Total Anomalous Pulmonary Venous Connection -- Child at TriStar Centennial DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...

Objective: To analyse the diagnostic value of multi-slice spiral CT and magnetic resonance imaging in treatment of Hepatic Veno-Occlusive Disease (HVO..

FDA Approves Defibrotide for Patients who Develop Hepatic Veno-Occlusive Disease After Transplant - Latest & Greatest, News - ASH Clinical News

M. McDermott wrote: , , If you have any information regarding this malady, it is desperately , needed. A friends baby is suffering from this and they are desperate , for information re: treatments, research, names of doctors involved in , research etc..... If you have access to this information please help , me..Can you post and/or email any info to Scubadyver at aol.com Thank you Before I send you off on a wild goose chase, I should mention a pulmonary form of this illness in newborns. Here is a brief outline: Pulmonary Lymphangiectasia Clinical Presentation: Respiratory distress in a newborn. Etiology/Pathophysiology: Complete pulmonary venous atresia leads to pulmonary venous obstruction which results in engorged pulmonary lymphatics and capillaries. Heart size is normal since flow through the left side of the heart is decreased. Usually is fatal. Classified into 3 types: (1) Pulmonary lymphangiectasia associated with congenital heart lesions characterized by obstruction of pulmonary venous ...

A condition in which the pulmonary veins that bring oxygen-rich blood from the lungs back to the heart are not connected to the left atrium, but instead, drain elsewhere.

This report studies the Global Veno-Occlusive Hepatic Disease Therapeutics Market 2017, analyzes and researches the Veno-Occlusive Hepatic Disease Therapeu

A diagnosis of congenital unilateral pulmonary vein atresia (CUPVA) was made. The patient experienced shortness of breath only after intense exercise and there was no pulmonary infection or recurrent haemoptysis. She was closely monitored, and light-intensity physical activity was permitted.. Unilateral diffuse pulmonary parenchymal lesions are clinically rare. The causes of these lesions include focal chronic inflammatory diseases, such as bronchiectasis and gastro-oesophageal reflux, radiation pneumonitis and mechanical ventilation of a unilateral lung.1 Unilateral diffuse pulmonary parenchymal lesions have also been reported in diseases, such as Sjogrens syndrome and systemic sclerosis.1 Additional rare causes of unilateral lesions include pulmonary circulatory diseases, such as proximal PA blockage (eg, PA sarcoma), venous thrombosis and unilateral pulmonary vein stenosis due to mediastinal fibrosis. In adult patients with CUPVA, long-term pulmonary circulation abnormalities can cause ...

Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring , 15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and requiring , 300cc of packed red blood cells/24 hours, or an adult patient weighing 70 kg and requiring ,3 units of packed red blood cells/24 hours) to replace blood loss, OR bleeding from a site which in the Investigators opinion constitutes a potential life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of amount of blood loss, at any point from the date of SCT through the date of severe VOD diagnosis ...

Clinically significant uncontrolled acute bleeding, defined as hemorrhage requiring , 15 cc/kg of packed red blood cells (e.g., a pediatric patient weighing 20 kg and requiring , 300cc of packed red blood cells/24 hours, or an adult patient weighing 70 kg and requiring ,3 units of packed red blood cells/24 hours) to replace blood loss, OR bleeding from a site which in the Investigators opinion constitutes a potential life-threatening source (e.g. pulmonary hemorrhage or CNS bleeding), irrespective of amount of blood loss, at any point from the date of SCT through the date of severe VOD diagnosis ...

Isolated stenosis of pulmonary veins, as they enter into the left atrium, is a rare congenital cardiac abnormality. It is a serious lesion that has significant impact on clinical outcome. Significant and progressive pulmonary hypertension leads to rapid deterioration and death often before infancy, hence early recognition is vital for optimum management. In our case, right heart failure was initially attributed to pulmonary hypertension secondary to chronic lung disease. With a background of early prematurity, extended periods of ventilation and prolonged oxygen support, a similar clinical scenario is not uncommon in current paediatric practice. A history of wheezing also prompts clinicians to think primarily of chronic lung disease.. Symptoms of pulmonary vein stenosis are also quite similar, i.e., respiratory distress and evolving cardiac failure. In the early neonatal period, the condition has increasingly been recognized as a cause of persistent pulmonary hypertension of the newborn1 in the ...

Paper: Veno-occlusive procedures for Control of Bleeding Oesophageal Varices Sclerotherapy Versus Surgery , Author: Shedid NM. FRCS; Kamal MA. MD; Nassar AK MD; Yehia A. MD; El-Soueni H. MD;El Samanody A. MD; El-Sayed El Kilany. MD. , Year: , Faculty of Medicine, Benha University

Other names: pulmonary congestion, congestion of blood in the lungs Pulmonary congestion is not a classic symptom of subjective, but rather a sign of a disease on chest radiograph, which alerts the clinician to either lung disease or heart. However, it may manifest dyspnea and bloody sputum secretion. Technically this phenomenon called pulmonary congestion (stasis of blood in the lungs). It may mean that the heart can not handle pump blood into the large circulation and it then accumulates in the small circulation - in pulmonary vessels. These radiographic appears to be widespread, highlighted. When judgment is advanced to pulmonary edema (pulmonary edema when the fluid passes from the blood vessels into the lung tissue). Such heart failure are often elderly people from various causes (degenerative valvular defects, heart attack, high blood pressure, …) or even small children from birth if they have some developmental heart defects often more serious nature. At other times, however, slight pulmonary

Introduction. Placement of the central vein catheterization (CVC) is a major risk factor for central vein stenosis (CVS). Repetitive endothelial exposures to the CVC results in inflammation, microthrombi formation, hyperplasia of the intima, fibrosis and thus development of CVS. The study aimed to find out the correlation between the duration and frequency of CVC in patients with CVS. Method. A matched case-control study was conducted in dr. Cipto Mangunkusumo General Hospital. Samples were taken from the medical record. Multivariate statistical comparisons were done using Chi-square tests. Results. Fifty-four out of 717 patients underwent CVC for hemodialysis had CVS. A total of 32 patients with CVS enrolled in the study with 128 non-CVS patients as a control. Duration of CVC |6 weeks does not increase the risk of CVS (p = 0.207), whilst the odds ratio of CVS on the frequency of CVC |2 times is 30 times compared to those underwent 2 times increased the risk of CVS. Longer duration of CVC for

Hepatic venous outflow block caused by short-length hepatic vein stenoses. - D Valla, A Hadengue, M el Younsi, N Azar, G Zeitoun, M J Boudet, G Molas, J Belghiti, S Erlinger, J M Hay, J P Benhamou

That sell-off would be warranted if the companys profits were about to plummet, but I think there are reasons to expect the opposite. Xyrem is currently being used by less than 10% of patients in the U.S. who are believed to have narcolepsy, which hints at there being plenty of room left for the drug to grow. Jazz also has a decent pipeline of drugs in late-stage trials that should help it extend its leadership position in the sleep market and also expand its presence in the hematology and oncology markets.. The FDA is also currently reviewing Jazzs Defitelio for approval. Defitelio was submitted as a potential treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation therapy. I think the chances are good for a regulatory thumbs-up since its already approved for sale in Europe, and the FDA has given it submission fast-track designation. We should have an answer by the end of March, with analysts forecasting that the drug ...

Defibrotide works by increasing the breakdown of clots in the blood. Defibrotide is used to treat severe veno-occlusive disease (VOD) in adults and children who have undergone chemotherapy and a stem-cell transplant. VOD happens when blood vessels in the liver become blocked, which decreases blood flow and can lead to...

Italian drugmaker Gentium has pulled its US marketing application for defibrotide, a drug for veno-occlusive disease (VOD), after it became clear that the Food and Drug Administration would not accept the filing. - News - PharmaTimes

Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.

Patients who have previously received a hematopoietic stem cell transplant (HSCT) are at higher risk for veno-occlusive disease (VOD) of the liver following treatment with clofarabine (40 mg/m2) when used in combination with etoposide (100 mg/m2) and cyclophosphamide (440 mg/m2). Severe hepatotoxic events have been reported in a combination study of clofarabine in pediatric patients with relapsed or refractory acute leukemia. Two cases (2%) of VOD in the mono-therapy studies were considered related to study drug. Monitor for and discontinue Clolar if VOD is suspected ...

Dr. Mark Milunski answered: Pulm edema: A matter of semantics to some physicians. The terms are often used interchangeably to describe fluid build-up in the l...

Lombard Medical Technologies (NSDQ:EVAR) said yesterday that its bailing out of the U.S. market after an FDA decision requiring a 50-patient clinical study of its Intelliflex low-profile delivery system for the Aorfix stent graft. Lombard said it eliminated its U.S. sales force and moved most of its commercial operations to its U.K. facility, significantly reducing its cash burn. Irvine, […]. ...